Prelude Therapeutics Incorporated Insider Trading

PRLD

⊜ Compare

Last 12 months

Insiders bought $12.5M on the open market and sold nothing.

Net open-market

+$12.5M

1 buy · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

1 / 0

executives and directors

Last open-market buy

Apr 2026

Apr 21, 2026

Get an email when PRLD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Apr 21	David P Bonita Director	Bought 2 parts	2,815,315	$4.44 average	$12.5M	New	Form 4
Apr 21	Orbimed Genesis GP LLC Large holder	Bought 2 parts	2,815,315	$4.44 average	$12.5M	New	Form 4
Mar 25, 2025	Andrew Combs Chief Chemistry Officer	Bought	100,000	$0.69	69K	26%	Form 4
Mar 25, 2025	Krishna Vaddi CEO	Bought	675,000	$0.69	466K	36%	Form 4
Mar 20, 2025 – Mar 21, 2025	Krishna Vaddi CEO	Bought 2 parts	20,416	$0.73 average	15K	1.1%	Form 4
Mar 14, 2025 – Mar 17, 2025	Krishna Vaddi CEO	Bought 2 parts	39,105	$0.75 average	29K	2.1%	Form 4
Mar 12, 2025 – Mar 13, 2025	Krishna Vaddi CEO	Bought 2 parts	97,500	$0.72 average	70K	5.2%	Form 4
Dec 31, 2024	Krishna Vaddi CEO	Bought	5,000	$1.21	6K	0.2%	Form 4
Dec 30, 2024	Krishna Vaddi CEO	Bought	10,000	$1.20	12K	0.4%	Form 4
Dec 20, 2024 – Dec 23, 2024	Andrew Combs Chief Chemistry Officer	Bought 2 parts	63,075	$1.36 average	86K	20%	Form 4
Dec 19, 2024	Bryant David Lim CLO, Interim CFO, Corp Sec.	Bought	25,000	$0.91	23K	1042%	Form 4
Dec 18, 2024 – Dec 19, 2024	Krishna Vaddi CEO	Bought 2 parts	106,888	$0.93 average	99K	6.1%	Form 4

Apr 21
David P Bonita
Director · bought 2,815,315 at avg $4.44
$12.5M
New position
Apr 21
Orbimed Genesis GP LLC
Large holder · bought 2,815,315 at avg $4.44
$12.5M
New position
Mar 25, 2025
Andrew Combs
Chief Chemistry Officer · bought 100,000 at $0.69
69K
26% of stake
Mar 25, 2025
Krishna Vaddi
CEO · bought 675,000 at $0.69
466K
36% of stake
Mar 20, 2025 – Mar 21, 2025
Krishna Vaddi
CEO · bought 20,416 at avg $0.73
15K
1.1% of stake
Mar 14, 2025 – Mar 17, 2025
Krishna Vaddi
CEO · bought 39,105 at avg $0.75
29K
2.1% of stake
Mar 12, 2025 – Mar 13, 2025
Krishna Vaddi
CEO · bought 97,500 at avg $0.72
70K
5.2% of stake
Dec 31, 2024
Krishna Vaddi
CEO · bought 5,000 at $1.21
6K
0.2% of stake
Dec 30, 2024
Krishna Vaddi
CEO · bought 10,000 at $1.20
12K
0.4% of stake
Dec 20, 2024 – Dec 23, 2024
Andrew Combs
Chief Chemistry Officer · bought 63,075 at avg $1.36
86K
20% of stake
Dec 19, 2024
Bryant David Lim
CLO, Interim CFO, Corp Sec. · bought 25,000 at $0.91
23K
1042% of stake
Dec 18, 2024 – Dec 19, 2024
Krishna Vaddi
CEO · bought 106,888 at avg $0.93
99K
6.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PRLD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PRLD

CompareIntrinsic value

JANXJanux Therapeutics Inc.

$18.18+2.02%40

EVFMEvofem Biosciences Inc.

$0.01+0.00%15

BGMBGM Group Ltd.

$8.81-7.65%26

SLGLSol-Gel Technologies Ltd.

$66.00+3.43%65

ZYBTZhengye Biotechnology Holding Ltd.

$1.37+2.24%9

SCYXScynexis, Inc.

$3.84-2.54%40

CTMXCytomX Therapeutics Inc.

$2.35+7.80%10

QUREuniQure N.V.

$23.07-3.35%10

Held by ETFs

PRLD is in 3 US ETFs. The largest of them, with PRLD's weight in each:

Spot a number that looks wrong? Check it in PRLD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PRLD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.